SCHEMBL15895115

SCHEMBL15895115

NOC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNC(=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.34
PTGS1 P23219 4/20 0.33
PTGS2 P35354 4/20 0.33
FAAH O00519 2/20 0.31
POLB P06746 1/20 0.31
HSP90AA1 P07900 1/20 0.30
TLR9 Q9NR96 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
HPGD P15428 1/20 0.30
XBP1 P17861 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
RECQL P46063 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15895162 0.92 MGLL (0.36) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL14655039 0.89 PTGS1 (0.40) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL15895109 0.84 PTGS1 (0.36) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL15892801 0.79 MGLL (0.39) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL10018581 0.79 MGLL (0.38) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL2226946 0.77 PTGS1 (0.42) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL10067024 0.76 PTGS1 (0.48) MGLLPTGS1PTGS2FAAHHSP90AA1
SCHEMBL15892740 0.75 MGLL (0.35) MGLLPTGS1PTGS2FAAHPOLB
SCHEMBL28486309 0.75 PTGS1 (0.38) MGLLPTGS1PTGS2FAAHPOLB
Hydrochloric Acid SCHEMBL514510 0.75 PTGS1 (0.47) MGLLPTGS1PTGS2FAAHHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9907854-B2 Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof CellMosaic, Inc. (US) 2018-03-06 US disclosed
US-20170065726-A1 NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF CELLMOSAIC INC (US) 2017-03-09 US disclosed
US-9511150-B2 Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof CellMosaic, Inc. (US) 2016-12-06 US disclosed
US-8907079-B2 Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof CELLMOSAIC INC. (US) 2014-12-09 US disclosed
US-20140206903-A1 NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF CELLMOSAIC INC (US) 2014-07-24 US disclosed
WO-2013012961-A2 NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF CELLMOSAIC, LLC (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170065726-A1 NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF CD44, ADH1C, EPCAM MGLL 2653/4885PTGS1 4278/4885PTGS2 4543/4885
US-20140206903-A1 NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF CD44, ADH1C, EPCAM MGLL 2305/4885PTGS1 4233/4885PTGS2 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.